The company’s historic expertise in fine chemicals provides a platform for redefining purity requirements for active ingredients and maximizing their therapeutic potential, allowing it to explore new and untouched indications.

Provepharm’s strategy first bore fruit with the development of a new and patented method for synthesizing methylene blue. This new active ingredient enabled Provepharm to obtain marketing authorizations in over 30 countries and to pursue its expansion internationally, with the creation of a new affiliate in the UK since November 2023.

Provepharm has a range of hospital products and is positioned as the leader in dyes in Europe. By working closely with hospital practitioners, Provepharm is committed to develop specific tools and services to improve clinical practices.

For more information, please visit: https://www.provepharm.com/